Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do genetic polymorphisms alter patient response to inhaled bronchodilators?

7 Aug 2014

Abstract excerpt

INTRODUCTION: Short- and long-acting β agonists (SABA and LABA) are bronchodilators for treating asthma. Bronchodilator response (BDR) is quantified by measuring air expired in the first second during a forced expiratory maneuver, prior to and following inhalation of SABA. BDR has been associated with a significant degree of heterogeneity, in part attributable to genetic variation. Heritability, the proportion of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Chronic Obstructive Pulmonary Disease (COPD) Research
Share to Receptor Mechanisms and Signaling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25102170
DOI: 10.1517/17425255.2014.939956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do genetic polymorphisms alter patient response to inhaled bronchodilators?PMID 25102170Read ↗

Pharmacogenetics of β2-AgonistsSemantic proximity Read ↗

Treatment response heterogeneity in asthma: the role of genetic variation.Semantic proximity Read ↗

The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update.Semantic proximity Read ↗

Clinical consequences of ADRbeta2 polymorphisms.Semantic proximity Read ↗

Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: a genetic study.Semantic proximity Read ↗

Pharmacogenomics of long-acting β2-agonists.Semantic proximity Read ↗

Pharmacogenetics of asthma.Semantic proximity Read ↗

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.Semantic proximity Read ↗

Beta 2 Adrenergic Receptor Genetic Polymorphisms in Bronchial Asthma: Relationship to Disease Risk, Severity, and Treatment Response.Semantic proximity Read ↗

Beta2-adrenoceptor polymorphisms and obstructive airway diseases: important issues of study design.Semantic proximity Read ↗

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug TherapySemantic proximity Read ↗

Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.